Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high recurrence rate, suicide rate and disability rate. It's reported that the global burden caused by MDD will be up to the second rank among all the disease burdens by 2020. China is also confronted with the daunting challenges against MDD. It's assessed that the monthly incidence of MDD is 6.1%, non-hospitalizing rate reaches up to 92% and the non-treatment rate is approximate 95%. However, to date, the pathogenesis of MDD is obscure and the current therapies don't work well. Therefore, it's urgent and critical to elucidate the pathogenesis of MDD, to develop early diagnostic criteria and effective intervention in MDD. Considering the diversity of weights on genetic factor and environmental factor in MDD, in this project, the investigators aim firstly to explore the effect of "genetic-environmental interaction"on the pathogeny of MDD for classifying MDD into "genetic type", "environmental type" and "others" based on a case-control study. We next conduct the neurobiological, neurocognitive and psycho-behavioral assessments among MDD, schizophrenia and healthy groups to screen the salient endophenotypes for establishing the diagnostic models of MDD . The investigators further analyse the changes of these indicators after 8 weeks'medication to select the potential predictors for therapeutic evaluations and interventional options in MDD patients. Finally, the investigators continue a 2-year follow-up study to test and verify the predictors of prognosis in MDD patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
2,400
fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
Beijing Anding Hospital
Beijing, Beijing Municipality, China
RECRUITINGPeking Union Medical College Hospital
Beijing, Beijing Municipality, China
ACTIVE_NOT_RECRUITINGPeking University Sixth Hospital
Beijing, Beijing Municipality, China
RECRUITINGHebei Medical University First Hospital
Shijiazhuang, Hebei, China
ACTIVE_NOT_RECRUITINGDalian Seventh People's Hospital
Dalian, Liaoning, China
ACTIVE_NOT_RECRUITINGFirst Hospital of China Medical University
Shenyang, Liaoning, China
ACTIVE_NOT_RECRUITINGFirst Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
ACTIVE_NOT_RECRUITINGTianjin Anding Hospital
Tianjin, Tianjin Municipality, China
ACTIVE_NOT_RECRUITINGTianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
ACTIVE_NOT_RECRUITINGThe changes of HAMD total score at 8 weeks from baseline
The scores are assessed at 0,2,4,8 weeks since the medication begins for MDD group
Time frame: week 0,2,4,8
The changes of HAMA total score at 8 weeks from baseline
The scores are assessment at 0,2,4,8 weeks since the medication begins for MDD group
Time frame: week 0,2,4,8
The change of CGI score at 8 weeks from baseline
The scores are assessment at 0,2,4,8 weeks since the medication begins for MDD group
Time frame: week 0,2,4,8
The prognosis after the intervention
Time frame: Up to 2 years
Number of participants with serious and non-serious adverse events
Time frame: Up to two years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.